Magnecell is opening new channels to therapy with nanotechnology. We are developing revolutionary tissue engineering products by using magnetic nanoparticles to overcome major problems associated with the ex vivo growth of human tissues and cells.

The technique can activate targeted ion-channel cell receptors remotely without the need for drugs or other biochemical stimuli. The technology has multiple applications in controlling and targeting therapy in a wide range of diseases.

Our first product will be to repair cartilage damage caused by trauma and osteoarthritis. This will result in an out-patient procedure that will be significantly simpler and more cost effective than current treatments.

Magnecell's patented technology was developed from biomedical research at Keele University and the North Staffordshire NHS Trust.